Gastric Cancer, Hepatocellular Carcinoma
Conditions
Brief summary
This is a phase II, single arm, open-label study of two parallel cohorts (advanced stomach and gastroesophageal junction cancer and hepatocellular carcinoma), evaluating the effects of telatinib in combination with Keytruda on progression-free survival.
Interventions
Sponsors
EOC Pharma
Andrew Hendifar, MD
Study design
Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
TREATMENT
Masking
NONE
Eligibility
Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No
Inclusion criteria
* Diagnosis: Histologically confirmed gastric/esophagealgastric adenocarcinoma, recurrent, locally advanced or metastatic, PD-L1-positive disease (CPS ≥1), progressed on at least two prior lines of therapy and/or discontinued second line therapy for intolerance, indicated for Keytruda therapy. OR: Hepatocellular carcinoma with diagnosis confirmed by histologic or cytologic analysis or clinical features according to the American Association for the Study of Liver Diseases criteria for patients with cirrhosis, unresectable disease not amenable to locoregional therapy with disease progression after at least one prior line of systemic therapy or discontinued first line therapy for intolerance. * At least 1 measurable metastatic lesion that has not been irradiated. The lesion will be measured according to Response Evaluation Criteria in Solid Tumors (RECIST 1.1), and be documented by radiological evaluation within 28 days prior to registration. For subjects with locally advanced disease: at least one measurable lesion that has not been irradiated, documented by radiological evaluation within 28 days prior to registration. * Any prior radiation therapy must be completed at least 28 days prior to the first dose of study treatment. * Eighteen years of age or older. * Eastern Cooperative Oncology Group (ECOG) performance score of 0, 1 or 2. * Adequate bone marrow, liver, and renal function * Negative urine or serum pregnancy test for women of childbearing potential. * Women and men of childbearing potential must agree to use adequate contraception prior to registration, for the duration of study participation and until 4 months after the last study drug dosing. * Able to swallow tablets and agree to take the prescribed tablets twice daily.
Exclusion criteria
* Clinical or radiographic evidence of current brain metastasis. History of treated brain metastases is allowable. * Cardiac disease * Uncontrolled hypertension * Severe hemorrhage/bleeding event within 28 days prior to the first dose of study treatment * Major surgery, open biopsy, or significant traumatic injury within 42 days prior to the first dose of study treatment * Current serious, nonhealing wound, ulcer, or bone fracture within 42 days prior to the first dose of study treatment * History of abdominal fistula, gastrointestinal perforation, or intra-abdominal abscess within 6 months prior to the first dose of study treatment. * Presence of an uncontrolled infection or infection that required intravenous antibiotics, antifungals, or antivirals within 14 days prior to the first dose of study treatment. * Known human immunodeficiency virus (HIV) infection. HIV-infected subjects on effective anti-retroviral therapy are eligible if the most recent viral load test performed within six months of screening (based on medical chart review) is negative. The safety of telatinib in this subject population has not been studied. * Known chronic hepatitis B, unless receiving antiviral treatment. * Known Child-Pugh Score B or C liver cirrhosis. * Diagnosis of immunodeficiency or is receiving systemic steroid therapy or any other form of immunosuppressive therapy within 7 days prior to the first dose of study treatment or has been diagnosed with an autoimmune disease that has required systemic treatment in the past 2 years (i.e., with use of disease modifying agents, corticosteroids, or immunosuppressive drugs). Patients that require replacement therapy (e.g., thyroxine \[T4\], insulin, or physiologic corticosteroid replacement therapy for adrenal or pituitary insufficiency, etc.) may be enrolled. * History of (non-infectious) pneumonitis that required steroids, or current pneumonitis, or has a history of interstitial lung disease. * Has received a live-virus vaccination within 30 days of planned treatment start. * Known history of proteinuria \> 1gr/24 hours. * Previous or concurrent cancer that is distinct in primary site or histology from the current stomach or liver cancer. Subjects with cervical cancer in-situ, treated basal cell carcinoma, superficial bladder tumors (Ta and Tis) or any cancer curatively treated are not excluded. * Anti-cancer therapy (chemotherapy, hormonal therapy, radiation therapy, surgery, immunotherapy, biologic therapy, or tumor embolization) or investigational agent within 28 days prior to the first dose of study treatment. * Known or suspected allergy to any component of telatinib or Keytruda * Prior or current history of substance abuse, or medical, psychological, or social condition that in the opinion of the investigator may interfere with the subject's participation in the study or evaluation of the study result. * Women who are pregnant or breastfeeding. * Prior history of thromboembolic disease, e.g., deep vein thrombosis (DVT), pulmonary emboli (PE), within 6 months prior to the first dose of study treatment that has required continued medical intervention. * Baseline peripheral neuropathy.
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Progression-free Survival | through study completion, approximately 2.5 years | Duration of time from start of treatment until progression or death, whichever comes first |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Overall Response Rate | from the start of treatment until the end of treatment, approximately 12 months | The percentage of patients who have a partial or complete response to treatment |
| Disease Control Rate | from the start of treatment until the end of treatment, approximately 12 months | The percentage of patients who have stable disease, partial response, or complete response to treatment |
| Overall Survival | from the start of treatment until time-of-event | The length of time from the start of treatment that patients are still alive |
| Number and Severity of Adverse Events | from the start of treatment until 30 days following the end of treatment or until initiation of a new anticancer therapy (whichever occurs first), approximately 13 months | Incidence and severity of adverse events as measured by the National Cancer Institute Common Terminology Criteria for Adverse Events Version 5 |
Countries
United States
Participant flow
Recruitment details
The trial opened to accrual on 7/12/2021 with first subject enrolled on study 7/28/2021. A total of 23 patients consented; 5 subjects failed screening; 2 were withdrawn; 16 subjects went on treatment, 1 subject (subject 009) withdrew consent; 15 completed study intervention evaluable. The study was closed to accrual on 02/07/2023 due to discontinuation of support by the drug supplier and funding source, due to postulated limited potential utility of the study drug.
Participants by arm
| Arm | Count |
|---|---|
| Telatinib + Keytruda Telatinib: 900mg by mouth twice daily until disease progression, intolerable toxicities, or withdrawal of consent
Keytruda: 200mg intravenous infusion every three weeks until disease progression, intolerable toxicities, or withdrawal of consent
Single Arm with 2 Cohorts:
Cohort 1: Gastric/esophagealgastric adenocarcinoma, recurrent, locally advanced or metastatic, PD-L1-positive disease (CPS ≥1), progressed on at least two prior lines of therapy and/or discontinued second line therapy for intolerance, indicated for Keytruda therapy.
Cohort 2: Hepatocellular carcinoma, with diagnosis confirmed by histologic or cytologic analysis or clinical features according to the American Association for the Study of Liver Diseases criteria for patients with cirrhosis, unresectable disease not amenable to locoregional therapy with disease progression after at least one prior line of systemic therapy or discontinued first line therapy for intolerance. | 15 |
| Total | 15 |
Withdrawals & dropouts
| Period | Reason | FG000 |
|---|---|---|
| Overall Study | Withdrawal by Subject | 1 |
Baseline characteristics
| Characteristic | Telatinib + Keytruda |
|---|---|
| Age, Categorical <=18 years | 0 Participants |
| Age, Categorical >=65 years | 10 Participants |
| Age, Categorical Between 18 and 65 years | 5 Participants |
| Age, Continuous | 66.93 years STANDARD_DEVIATION 14.01 |
| Ethnicity (NIH/OMB) Hispanic or Latino | 3 Participants |
| Ethnicity (NIH/OMB) Not Hispanic or Latino | 12 Participants |
| Ethnicity (NIH/OMB) Unknown or Not Reported | 0 Participants |
| Race (NIH/OMB) American Indian or Alaska Native | 0 Participants |
| Race (NIH/OMB) Asian | 3 Participants |
| Race (NIH/OMB) Black or African American | 1 Participants |
| Race (NIH/OMB) More than one race | 0 Participants |
| Race (NIH/OMB) Native Hawaiian or Other Pacific Islander | 0 Participants |
| Race (NIH/OMB) Unknown or Not Reported | 0 Participants |
| Race (NIH/OMB) White | 11 Participants |
| Region of Enrollment United States | 15 participants |
| Sex: Female, Male Female | 3 Participants |
| Sex: Female, Male Male | 12 Participants |
Adverse events
| Event type | EG000 affected / at risk |
|---|---|
| deaths Total, all-cause mortality | 12 / 16 |
| other Total, other adverse events | 16 / 16 |
| serious Total, serious adverse events | 8 / 16 |
Outcome results
Primary
Progression-free Survival
Duration of time from start of treatment until progression or death, whichever comes first
Time frame: through study completion, approximately 2.5 years
| Arm | Measure | Value (MEAN) | Dispersion |
|---|---|---|---|
| telatinib + Keytruda | Progression-free Survival | 153.87 Days | Standard Deviation 133.69 |
Secondary
Disease Control Rate
The percentage of patients who have stable disease, partial response, or complete response to treatment
Time frame: from the start of treatment until the end of treatment, approximately 12 months
| Arm | Measure | Value (COUNT_OF_PARTICIPANTS) |
|---|---|---|
| telatinib + Keytruda | Disease Control Rate | 8 Participants |
Secondary
Number and Severity of Adverse Events
Incidence and severity of adverse events as measured by the National Cancer Institute Common Terminology Criteria for Adverse Events Version 5
Time frame: from the start of treatment until 30 days following the end of treatment or until initiation of a new anticancer therapy (whichever occurs first), approximately 13 months
| Arm | Measure | Category | Value (COUNT_OF_UNITS) |
|---|---|---|---|
| telatinib + Keytruda | Number and Severity of Adverse Events | Grade 1 | 161 Adverse Events (AEs) |
| telatinib + Keytruda | Number and Severity of Adverse Events | Grade 2 | 87 Adverse Events (AEs) |
| telatinib + Keytruda | Number and Severity of Adverse Events | Grade 3 | 57 Adverse Events (AEs) |
| telatinib + Keytruda | Number and Severity of Adverse Events | Grade 4 | 7 Adverse Events (AEs) |
| telatinib + Keytruda | Number and Severity of Adverse Events | Grade 5 | 1 Adverse Events (AEs) |
Secondary
Overall Response Rate
The percentage of patients who have a partial or complete response to treatment
Time frame: from the start of treatment until the end of treatment, approximately 12 months
| Arm | Measure | Value (COUNT_OF_PARTICIPANTS) |
|---|---|---|
| telatinib + Keytruda | Overall Response Rate | 0 Participants |
Secondary
Overall Survival
The length of time from the start of treatment that patients are still alive
Time frame: from the start of treatment until time-of-event
| Arm | Measure | Value (MEDIAN) |
|---|---|---|
| telatinib + Keytruda | Overall Survival | 258 days |